144 related articles for article (PubMed ID: 35585014)
41. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
[TBL] [Abstract][Full Text] [Related]
42. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014.
Stenman M; Sinclair G; Paavola P; Wersäll P; Harmenberg U; Lindskog M
Radiother Oncol; 2018 Jun; 127(3):501-506. PubMed ID: 29754859
[TBL] [Abstract][Full Text] [Related]
43. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
44. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
45. Surgical Management of Metastatic Adrenocortical Carcinoma.
Passman JE; Amjad W; Ginzberg SP; Soegaard Ballester JM; Finn C; Wachtel H
World J Surg; 2024 Jan; 48(1):110-120. PubMed ID: 38463201
[TBL] [Abstract][Full Text] [Related]
46. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
47. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
[TBL] [Abstract][Full Text] [Related]
48. Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR.
Yuan JH; Tanaka H; Patil D; Hakimi K; Soliman S; Meagher MF; Saidian A; Walia A; Dhanji S; Liu F; Afari J; Nguyen M; Wang L; Yasuda Y; Saito K; Fujii Y; Master V; Derweesh IH
Clin Genitourin Cancer; 2023 Aug; 21(4):e219-e227. PubMed ID: 36588000
[TBL] [Abstract][Full Text] [Related]
49. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.
Tornberg SV; Visapää H; Kilpeläinen TP; Taari K; Järvinen R; Erkkilä K; Nisen H; Järvinen P
Scand J Urol; 2018; 52(5-6):419-426. PubMed ID: 30663485
[TBL] [Abstract][Full Text] [Related]
50. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
51. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
Urol Oncol; 2016 Oct; 34(10):433.e1-8. PubMed ID: 27321354
[TBL] [Abstract][Full Text] [Related]
52. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis.
van der Poel HG; Roukema JA; Horenblas S; van Geel AN; Debruyne FM
Eur Urol; 1999; 35(3):197-203. PubMed ID: 10072620
[TBL] [Abstract][Full Text] [Related]
53. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: A systematic review and meta-analysis.
Zhao Y; Li J; Li C; Fan J; Liu L
Int J Surg; 2017 May; 41():70-77. PubMed ID: 28351779
[TBL] [Abstract][Full Text] [Related]
55. Deferred systemic therapy in patients with metastatic renal cell carcinoma.
Mitchell AP; Hirsch BR; Harrison MR; Abernethy AP; George DJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e159-66. PubMed ID: 25770767
[TBL] [Abstract][Full Text] [Related]
56. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
[TBL] [Abstract][Full Text] [Related]
57. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
58. Impact of facility type and volume on survival in patients with metastatic renal cell carcinoma.
Dursun F; Elshabrawy A; Wang H; Oelsen J; Liss M; Kaushik D; Ramamurthy C; Rodriguez R; Mansour AM
Can J Urol; 2021 Oct; 28(5):10806-10816. PubMed ID: 34657653
[TBL] [Abstract][Full Text] [Related]
59. [Metastasectomy for renal cell cancer].
Brehmer B; Piper C; Pfister D; Porres D; Heidenreich A
Urologe A; 2012 Sep; 51(9):1202-8. PubMed ID: 22733397
[TBL] [Abstract][Full Text] [Related]
60. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
